June 18, 2018

BUSINESS WIRE: Medacta Launches Short Humeral Diaphysis for the Medacta Shoulder System at the San Diego Shoulder Institute's Annual Shoulder Course

Medacta today announced clearance by the U.S. Food and Drug Administration (FDA) for its Short Humeral Diaphysis, which is utilized with the Medacta Shoulder System. The company will showcase this new product at the San Diego Shoulder Institute’s (SDSI) Annual Shoulder Course, held June 20-23 in San Diego at Booth #310.

The Short Humeral Diaphysis is an implantable device that replaces the humeral side of the gleno-humeral joint and is intended for use with the Medacta Shoulder System as an alternative to the Standard Humeral Diaphysis. The Short Humeral Diaphysis is indicated for primary and reverse shoulder replacement in patients suffering from severe arthropathy or a grossly deficient rotator cuff. Through a reduction in device length, the corresponding procedure minimizes the violation of the humeral intramedullary canal (IM). The device is manufactured from titanium alloy and will be offered in 11 sizes to provide a patient-matched fit.

“Medacta is constantly looking to expand its product offerings to accommodate the largest group of unique patient anatomies as possible,” said Francesco Siccardi, Executive Vice President of Medacta International. “We’ve experienced a very positive response to our recent expansion into the shoulder market and are looking to build on that success. The addition of the Short Humeral Diaphysis to the Medacta Shoulder System means that surgeons will be able to achieve a more personalized fit for more patients, improving the patient and surgeon experience.”